Microarray Core

基因组学核心的作用是支持该中心开展的研究项目， 最先进的转录分析和数据挖掘能力，涵盖广泛的样本类型。的 该中心将有权使用一个在过去7年中一直在连续运行的设施。它有 受益于贝勒医疗保健系统的持续投资， 最先进的基因组分析仪器和IT基础设施。数据将在 在严格控制的实验室环境中， 确保最高的数据质量和再现性。其他转录谱分析技术也是 可以通过这个核心，如实时PCR或NanoString平台。一组生物信息学家 已集成到核心，以开发和维护数据管理基础设施， 构成了其运作的支柱。定制数据管理和挖掘解决方案可用于 大量微阵列数据的最佳利用。生物信息学和生物统计学支持也将 提供给个体研究者用于分析他们的微阵列结果。微阵列核心 在BUR已经开展了基因组学和免疫学领域之间的接口项目，并获得了 在分析方面的重要专业知识：a）患有各种疾病的患者的血液; B）小细胞数量 分离自组织或细胞培养物; c）在体外暴露于广泛的先天刺激的血液;和d）血液 在抗原肽存在下培养。 将为所有项目和临床试验的机械组成部分提供支持， 被求婚更具体地说，将在项目1的背景下生成离体血液曲线 （Pascual），而对培养物中抗原再刺激的反应将在项目2的背景下进行分析 （Ueno）和试点项目（Chaussabel）。

The role of the genomics core is to support the research projects carried out by the center by providing state-of-the-art transcription profiling and data mining capabilities over a wide range of sample types. The center will have access to a facility that has been in continuous operation for the past 7 years. It has benefited from a continuous investment on the part of the Baylor Health Care System and has at its disposal state of the art genomic analysis instruments and IT infrastructure. Data will be generated on the high-through and cost-effective Illumina BeadArray platform in a strictly controlled laboratory environment to insure the highest data quality and reproducibility. Other transcriptional profiling technologies are also available through this core, such as real-time PCR or NanoString platforms. A team of bioinformaticians has been integrated to the core in order to develop and maintain the data management infrastructure that constitutes the backbone of its operation. Custom data management and mining solutions are available for the optimal exploitation of large volumes of microarray data. Bioinformatics and biostatistics support will also be made available to individual investigators for the analysis of their microarray results. The microarray core at BUR has carried out projects at the interface between the fields of genomics and immunology, and gained significant expertise in profiling: a) blood of patients with a wide range of diseases; b) small cell numbers isolated from tissues or cell cultures; c) blood exposed in vitro to a wide range of innate stimuli; and d) blood cultivated in the presence of antigenic peptides. Support will be provided across all the projects and mechanistic components of the clinical trials that are being proposed. More specifically, ex-vivo blood profiles will be generated in the context of project 1 (Pascual), while responses to antigen re-stimulation in culture will be profiled in the context of project 2 (Ueno) and the pilot project (Chaussabel).